目的 探讨阿托伐他汀联合贝那普利对高血压患者的降压疗效。方法 92例高血压患者，根据数字方法分成对照组和观察组，每组 46 例。对照组给予贝那普利口服治疗，观察组给予阿托伐他汀联合贝那普利口服治疗。比较两组患者治疗前后的动态血压[24 h 收缩压(SBP)、24 h 舒张压(DBP)、24 h脉压(PP)、24 h脉压指数(PPI)]、血脂[总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]水平、颈动脉内膜中层厚度(IMT)、超敏C反应蛋白(hs-CRP)水平以及安全性。结果 治疗后，观察组患者 24 h SBP(143。56±6。20)mm Hg(1 mm Hg=0。133 kPa)、24 h DBP(87。60±4。51)mm Hg、24 h PP(50。79±7。48)mm Hg均低于对照组的(148。12±8。63)、(90。18±5。35)、(56。67±5。32)mm Hg，差异明显(P<0。05);治疗后两组 24 h PPI水平无明显差异(P>0。05)。治疗后，观察组患者TC(4。02±0。75)mmol/L、TG(1。74±0。67)mmol/L、LDL-C(2。43±0。57)mmol/L均低于对照组的(5。13±1。10)、(2。04±0。58)、(2。83±0。62)mmol/L，差异明显(P<0。05);两组患者治疗后的HDL-C水平无明显差异(P>0。05)。治疗后，观察组患者IMT(0。73±0。10)mm、hs-CRP(3。27±1。20)mg/L低于对照组的(0。80±0。14)mm、(4。68±1。35)mg/L，差异明显(P<0。05)。治疗期间两组未出现明显药物不良反应。结论 阿托伐他汀联合贝那普利治疗高血压能提高降压疗效，患者的血脂水平得以调节，减轻炎症反应，稳定斑块，安全可靠。
Analysis of antihypertensive effect of atorvastatin combined with benazepril in patients with hypertension
Objective To explore the antihypertensive effect of atorvastatin combined with benazepril in patients with hypertension.Methods 92 patients with hypertension were divided into a control group and an observation group according to numerical method,with 46 cases in each group.The control group was treated with oral administration of benazepril,and the observation group was treated with oral administration of atorvastatin combined with benazepril.Patients in both groups were compared in terms of ambulatory blood pressure[24 h systolic blood pressure(SBP),24 h diastolic blood pressure(DBP),24 h pulse pressure(PP),24 h pulse pressure index(PPI)],blood lipids[total cholesterol(TC),triglycerides(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C)],carotid intima-media thickness(IMT),hypersensitive C-reactive protein(hs-CRP)level before and after treatments,and safety.Results After treatment,the observation group had 24 h SBP of(143.56±6.20)mm Hg(1 mm Hg=0.133 kPa),24 h DBP of(87.60±4.51)mm Hg,and 24 h PP of(50.79±7.48)mm Hg,which were lower than(148.12±8.63),(90.18±5.35)and(56.67±5.32)mm Hg in the control group,and the difference was significant(P<0.05).There was no significant difference in 24 h PPI level between the two groups after treatment(P>0.05).After treatment,the observation group had TC of(4.02±0.75)mmol/L,TG of(1.74±0.67)mmol/L and LDL-C of(2.43±0.57)mmol/L,which were lower than(5.13±1.10),(2.04±0.58)and(2.83±0.62)mmol/L in the control group,and the difference was significant(P<0.05).There was no significant difference in HDL-C levels between the two groups after treatment(P>0.05).After treatment,the observation group had IMT of(0.73±0.10)mm and hs-CRP of(3.27±1.20)mg/L,which were lower than(0.80±0.14)mm and(4.68±1.35)mg/L in the control group,and the difference was significant(P<0.05).There were no obvious adverse drug reactions in the two groups during treatment.Conclusion Atorvastatin combined with benazepril in the treatment of hypertension can improve the antihypertensive effect,regulate the blood lipid level of patients,reduce inflammation,stabilize plaque,and it is safe and reliable.
万方数据
维普
